Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants
The Journal of Rural Health · 2025
DOI: 10.1111/jrh.12857 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Rural Health, 2025. Verfasst von A Jerrod Anzalone und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: COVID-19, Rural Population, SARS-CoV-2, Urban Population. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCATS U24, NCATS NIH HHS.
Abstract (Originalsprache)
Purpose
To investigate the enduring disparities in adverse COVID‐19 events between urban and rural communities in the United States, focusing on the effects of SARS‐CoV‐2 vaccination and therapeutic advances on patient outcomes.
Methods
Using National COVID Cohort Collaborative (N3C) data from 2021 to 2023, this retrospective cohort study examined COVID‐19 hospitalization, inpatient death, and other adverse events. Populations were categorized into urban, urban‐adjacent rural (UAR), and nonurban‐adjacent rural (NAR). Adjustments included demographics, variant‐dominant waves, comorbidities, region, and SARS‐CoV‐2 treatment and vaccination. Statistical methods included Kaplan‐Meier survival estimates, multivariable logistic, and Cox regression.
Findings
The study included 3,018,646 patients, with rural residents constituting 506,204. These rural dwellers were older, had more comorbidities, and were less vaccinated than their urban counterparts. Adjusted analyses revealed higher hospitalization odds in UAR and NAR (aOR 1.07 [1.05–1.08] and 1.06 [1.03–1.08]), greater inpatient death hazard (aHR 1.30 [1.26–1.35] UAR and 1.37 [1.30–1.45] NAR), and greater risk of other adverse events compared to urban dwellers. Delta increased, while Omicron decreased, inpatient adverse events relative to pre‐Delta, with rural disparities persisting throughout. Treatment effectiveness and vaccination were similarly protective across all cohorts, but dexamethasone post‐ventilation was effective only in urban areas. Nirmatrelvir/ritonavir and molnupiravir better protected rural residents against hospitalization.
Conclusions
Despite advancements in treatment and vaccinations, disparities in adverse COVID‐19 outcomes persist between urban and rural communities. The effectiveness of some therapeutic agents appears to vary based on rurality, suggesting a nuanced relationship between treatment and geographic location while highlighting the need for targeted rural health care strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Nebraska Medical Center, Omaha, Nebraska, USA.
- University of Oklahoma, Norman, Oklahoma, USA.
- Maine Health Institute for Research, Portland, Maine, USA.
- University of Mississippi Medical Center, Jackson, Mississippi, USA.
- Christiana Care Health System, Newark, Delaware, USA.
- University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA.
ORCID-Profile: A Jerrod Anzalone, William H Beasley, William B Hillegass, Michael T Vest, Scott A Chapman, Ronald Horswell, Lucio Miele, J Zachary Porterfield, Sharon Patrick, Clifford J Rosen, Susan L Santangelo, James C McClay, Sally L Hodder
Förderung
- NIGMS NIH HHS
- NCATS U24
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institute of General Medical Sciences
Zitieren
APA
Anzalone, A. J., Beasley, W. H., Murray, K., Hillegass, W. B., Schissel, M., Vest, M. T., Chapman, S. A., Horswell, R., Miele, L., Porterfield, J. Z., Bunnell, H. T., Price, B. S., Patrick, S., Rosen, C. J., Santangelo, S. L., McClay, J. C., Hodder, S. L., & National COVID Cohort Collaborative (N3C) Consortium (2025). Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants. The Journal of Rural Health. https://doi.org/10.1111/jrh.12857
Vancouver
Anzalone AJ, Beasley WH, Murray K, Hillegass WB, Schissel M, Vest MT, et al. Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants. The Journal of Rural Health. 2025. doi:10.1111/jrh.12857
BibTeX
@article{Anzalone2025,
author = {Anzalone, A Jerrod and Beasley, William H and Murray, Kimberly and Hillegass, William B and Schissel, Makayla and Vest, Michael T and Chapman, Scott A and Horswell, Ronald and Miele, Lucio and Porterfield, J Zachary and Bunnell, H Timothy and Price, Bradley S and Patrick, Sharon and Rosen, Clifford J and Santangelo, Susan L and McClay, James C and Hodder, Sally L and National COVID Cohort Collaborative (N3C) Consortium, National COVID Cohort Collaborative (N3C) Consortium},
title = {Associations between COVID‐19 therapies and outcomes in rural and urban America: A multisite, temporal analysis from the Alpha to Omicron SARS‐CoV‐2 variants},
journal = {The Journal of Rural Health},
year = {2025},
doi = {10.1111/jrh.12857}
}
EUVIMED